Xth Eurasian Hematology-Oncology Congress

http://www.ehog.net/

 

Overcoming Resistance in HER2+ Metastatic Breast Cancer: Inhibiting HER2 Signalling More Effectively w/ Dual Blockade, Antibodies, Bispecific Antibodies, Novel TKIs, Anti-HER2 + CPis, CDK4-6 or PI3K/AKT/mTOR

90 views
December 4, 2019
0 Comments
Login to view comments. Click here to Login